657 related articles for article (PubMed ID: 18843256)
1. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG
Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256
[TBL] [Abstract][Full Text] [Related]
2. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
Abu-Alfa AK
Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
[TBL] [Abstract][Full Text] [Related]
3. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience.
Chrysochou C; Buckley DL; Dark P; Cowie A; Kalra PA
J Magn Reson Imaging; 2009 Apr; 29(4):887-94. PubMed ID: 19306428
[TBL] [Abstract][Full Text] [Related]
5. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis.
Weinreb JC; Kuo PH
Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
[TBL] [Abstract][Full Text] [Related]
7. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
8. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.
Nayak AB; Luhar A; Hanudel M; Gales B; Hall TR; Finn JP; Salusky IB; Zaritsky J
Pediatr Nephrol; 2015 Mar; 30(3):515-21. PubMed ID: 25212105
[TBL] [Abstract][Full Text] [Related]
9. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
[TBL] [Abstract][Full Text] [Related]
10. Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD.
Mukundan S; Steigner ML; Hsiao LL; Malek SK; Tullius SG; Chin MS; Siedlecki AM
Am J Kidney Dis; 2016 Jun; 67(6):984-8. PubMed ID: 26786296
[TBL] [Abstract][Full Text] [Related]
11. USPIO-Enhanced MRI Neuroimaging: A Review.
Gkagkanasiou M; Ploussi A; Gazouli M; Efstathopoulos EP
J Neuroimaging; 2016; 26(2):161-8. PubMed ID: 26932522
[TBL] [Abstract][Full Text] [Related]
12. Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research.
Simon GH; Raatschen HJ; Wendland MF; von Vopelius-Feldt J; Fu Y; Chen MH; Daldrup-Link HE
Acad Radiol; 2005 Sep; 12(9):1190-7. PubMed ID: 16099684
[TBL] [Abstract][Full Text] [Related]
13. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
[TBL] [Abstract][Full Text] [Related]
14. [Kidney and iodinated and gadolinium-based contrast agents].
Clément O; Faye N; Fournier L; Siauve N; Frija G
J Radiol; 2011 Apr; 92(4):291-8. PubMed ID: 21549885
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
[TBL] [Abstract][Full Text] [Related]
16. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety.
Juluru K; Vogel-Claussen J; Macura KJ; Kamel IR; Steever A; Bluemke DA
Radiographics; 2009; 29(1):9-22. PubMed ID: 19019996
[TBL] [Abstract][Full Text] [Related]
17. Specific targeting of breast tumor by octreotide-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 3.0-Tesla magnetic resonance scanner.
Li X; Du X; Huo T; Liu X; Zhang S; Yuan F
Acta Radiol; 2009 Jul; 50(6):583-94. PubMed ID: 19449236
[TBL] [Abstract][Full Text] [Related]
18. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
Heverhagen JT; Krombach GA; Gizewski E
Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
[TBL] [Abstract][Full Text] [Related]
19. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
Yancy AD; Olzinski AR; Hu TC; Lenhard SC; Aravindhan K; Gruver SM; Jacobs PM; Willette RN; Jucker BM
J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
[TBL] [Abstract][Full Text] [Related]
20. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
